Mersana Therapeutics (MRSN) Stock Price, News, Quotes-Moomoo

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Truist Financial Maintains Mersana Therapeutics(MRSN.US) With Buy Rating
Moomoo NewsMar 4 08:31 ET · Ratings
Mersana Therapeutics Full Year 2024 Earnings: Beats Expectations
Yahoo FinanceMar 4 06:07 ET
Mersana Therapeutics' Viability in Question Amidst Persistent Financial Losses and Funding Challenges
TipRanksMar 4 01:01 ET
Q4 2024 Mersana Therapeutics Inc Earnings Call
Yahoo FinanceMar 3 23:09 ET
William Blair Maintains Mersana Therapeutics(MRSN.US) With Buy Rating
Moomoo NewsMar 3 15:31 ET · Ratings
Mersana Therapeutics: Strong Buy Rating Backed by Robust Financial Performance and Strategic Market Positioning
TipRanksMar 3 14:55 ET · Ratings

Comments

Teddy123

Mar 3 06:30

Oncology updates - Emi-Le

$Mersana Therapeutics (MRSN.US)$
Mersana's clinical progress with Emi-Le (emiltatug ledadotin) represents a significant development in the B7-H4-targeted ADC landscape. The initial Phase 1 data from 130 patients shows promising activity across multiple tumor types, with particular emphasis on heavily pretreated triple-negative breast cancer (TNBC)—an area with substantial unmet medical need.
The expansion cohort at 67.4 mg/m² administered every four weeks in TNBC patient...

Teddy123

Mar 3 06:28

Financial Analysis

$Mersana Therapeutics (MRSN.US)$
Mersana's Q4 and full-year 2024 results illustrate a significant financial improvement amid promising clinical developments. Their net loss narrowed substantially to $69.2 million ($0.56/share) for 2024, down from $171.7 million ($1.48/share) in 2023. This 59.7% reduction reflects successful restructuring efforts and strategic pipeline focus.
The company reported Q4 collaboration revenue of $16.4 million, up 53.3% from the year-ago period, drive...

Teddy123

Mar 3 06:02

Mersana Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2024 Financial Results

$Mersana Therapeutics (MRSN.US)$
Mersana's ADC Pipeline Advances: FDA Fast Track Designation as Q4 Losses Narrow

Teddy123

Jan 30 07:22

Mersana Therapeutics to Participate in the Guggenheim SMID Cap Biotech Conference

$Mersana Therapeutics (MRSN.US)$
What is Mersana Therapeutics' (MRSN) main focus in cancer treatment?
Mersana Therapeutics focuses on discovering and developing antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need.
Exclusive: Mersana Therapeutics CEO to Reveal ADC Pipeline Updates at Guggenheim Conference

WeiTheSaint469

Jan 24 14:45

lfg

$Mersana Therapeutics (MRSN.US)$

1

MRSN Mersana Therapeutics

Trade Overview

Capital Trend

News

Comments

Trending Stocks